Veracyte Inc (OQ:VCYT)

Apr 16, 2024 08:30 am ET
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at AUA 2024, the annual meeting of the American Urological Association, taking place May 3-6 in San Antonio. Studies to be presented include those that eval
Feb 27, 2024 05:55 pm ET
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification
Feb 22, 2024 04:05 pm ET
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2023.
Feb 21, 2024 05:00 pm ET
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and John Leite, Ph.D., chief commercial officer, CLIA, will present at the Raymond James 45th Annual Institutional Investors Conference on Monday, March 4, 2024, at 9:50 a.m. Eastern Time.
Feb 08, 2024 08:00 am ET
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2023 after the close of market on Thursday, February 22, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day
Feb 06, 2024 08:15 am ET
Veracyte Completes Acquisition of C2i Genomics
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform and expanding the company’s ability to serve patients across the cancer care continuum.
Jan 08, 2024 08:00 am ET
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2023. The company also announced it has reached a definitive agreement to acquire C2i Genomics, Inc. a minimal residual disease (MRD) detection company, adding whole-genome M
Dec 12, 2023 04:30 pm ET
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 1:30 p.m. Pacific Time.
Dec 01, 2023 04:05 pm ET
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented today at the 24th Annual Meeting of the Society of Urologic Oncology (SUO 2023) highlight clinical observations and translational research conducted by users of the company’s Decipher Prostate Genomic Classifier. These independent, real-world studies provide further evidence supporting the
Nov 29, 2023 08:30 am ET
Nov 22, 2023 08:30 am ET
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
Veracyte, Inc. (Nasdaq: VCYT) today announced that seven posters will be presented at the
Nov 07, 2023 04:05 pm ET
Veracyte Announces Third Quarter 2023 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2023.
Nov 07, 2023 04:00 pm ET
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
Veracyte, Inc. (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina,
Nov 02, 2023 08:15 am ET
Veracyte to Participate in the Stephens Annual Investment Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Stephens Annual Investment Conference on Wednesday, November 15, at 3:00 p.m. Eastern Time.
Oct 27, 2023 08:30 am ET
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster presentations taking place at SITC 2023, the annual meeting of the Society for Immunotherapy of Cancer, in San Diego from November 3-5 will demonstrate the potential for using the company’s novel tools to help advance the development of immuno-oncology drugs. These tools allow for better char
Oct 17, 2023 08:15 am ET
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2023 after the close of market on Tuesday, November 7, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Oct 12, 2023 09:00 am ET
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the American College of Chest Physicians (CHEST) Annual Meeting 2023 demonstrate the clinical utility of the company’s Envisia Genomic Classifier, which is used by physicians to improve diagnostic and prognostic confidence of interstitial lung diseases (ILDs). The studies also un
Oct 04, 2023 04:05 pm ET
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, randomized phase 3 trial reinforce the value of the Decipher Prostate Genomic Classifier in helping physicians make more informed treatment decisions for their patients with prostate cancer. The findings, presented at the 2023 American Society for Radiation Oncology (ASTRO) Annu
Sep 28, 2023 04:05 pm ET
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data presented at the 2023 American Thyroid Association (ATA) Annual Meeting demonstrate the type of novel molecular insights for thyroid nodules and cancer that are enabled by analysis with the Afirma Genomic Sequencing Classifier (GSC). Presented by clinical researchers in three posters, the fin
Sep 28, 2023 08:15 am ET
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company’s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.
Sep 27, 2023 09:00 am ET
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
Veracyte, Inc. (Nasdaq: VCYT) today announced that Phillip G. Febbo, M.D., will join the company on October 2 as chief scientific officer and chief medical officer. Dr. Febbo, a distinguished industry and academic leader, will lead Veracyte’s global team of research and development, medical affairs, clinical affairs, quality, regulatory affairs, and
Sep 21, 2023 04:05 pm ET
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s Afirma Genomic Sequencing Classifier (GSC) will be presented at the 2023 American Thyroid Association (ATA)
Sep 07, 2023 04:05 pm ET
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine, Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France. She will lead the global expansion of Veracyte’s tests and will also serve as site lead for the company’s Marseille operations. Dr. Taine is a highl
Sep 06, 2023 08:15 am ET
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerat
Aug 29, 2023 08:15 am ET
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, at 4:15 p.m. Eastern Time.
Aug 15, 2023 04:15 pm ET
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
Veracyte, Inc. (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces. Veracyte’s South San Francisco location has been awarded a
Aug 08, 2023 04:05 pm ET
Veracyte Announces Second Quarter 2023 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023.
Aug 01, 2023 08:15 am ET
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
Veracyte, Inc. (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic Classifier’s ability to guide personalized treatment approaches for men with prostate cancer. The study utilized data from the first linkage of prostate cancer cases reported by central cancer registries participating in the S
Jul 19, 2023 05:00 pm ET
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Jun 20, 2023 08:31 am ET
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual meeting of The Endocrine Society, suggest the company’s Afirma molecular testing and whole-transcriptome capabilities can provide novel insights that may advance the scientific understanding of thyroid nodule biology. In addition, findings from an analytical valid
Jun 12, 2023 08:31 am ET
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting new data on the company’s Afirma test and capabilities will be presented at ENDO 2023, the annual meeting of The Endocrine Society, which is taking place June 15-18 in Chicago, Ill. Additionally, Veracyte’s medical director of Endocrinology, Joshua Klopper, M.D., will partic
May 31, 2023 10:55 am ET
May 25, 2023 05:13 pm ET
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced that new data to be shared at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting demonstrate the ability of the company’s Decipher Genomics Resource for Intelligent Discovery (GRID) database to enable novel molecular insights into prostate cancer. The findings, from three separate studies, may
May 24, 2023 09:00 am ET
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D
May 23, 2023 05:00 pm ET
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences:
May 12, 2023 06:15 am ET
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced that new data show the use of the Prosigna Breast Cancer Assay altered treatment decisions for patients with early-stage breast cancer, including significantly reducing the use of chemotherapy among those with clinically high-risk disease. The findings are from EMIT, a prospective, multi-year, population-based
May 04, 2023 04:05 pm ET
Veracyte Announces First Quarter 2023 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2023.
May 04, 2023 09:45 am ET
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
Veracyte, Inc. (Nasdaq: VCYT) announced findings from a large-scale, systematic literature review showing that TERT promoter gene mutations in thyroid nodules deemed indeterminate by cytopathology are rare, but have a high risk of malignancy and, in certain cases, are associated with aggressive tumor behavior. The data are being presented at th
May 03, 2023 08:30 am ET
Veracyte Announces Release of Inaugural ESG Report
Veracyte, Inc. (Nasdaq: VCYT) today announced that it released its inaugural
May 01, 2023 05:35 pm ET
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts focused on the company’s genomic tests for interstitial lung disease (Envisia Genomic Classifier) and lung cancer (Percepta Nasal Swab) will be presented at the American Thoracic Society (ATS) 2023 International Conference. The meeting will take place May 19-24 in Washington, D.C.
Apr 29, 2023 04:31 pm ET
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the real-world performance and clinical utility of the company’s Decipher Prostate Genomic Classifier. The findings are from two separate, large-scale studies evaluating the Decipher Prostate test among a total of m
Apr 27, 2023 04:05 pm ET
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
Veracyte, Inc. (Nasdaq: VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago and online June 2-6. Three of the accepted abstracts leverage Veracyte’s Decipher GRID (Genomic Resource for
Apr 13, 2023 05:00 pm ET
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2023 after the close of market on Thursday, May 4, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Apr 12, 2023 08:30 am ET
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts highlighting new data from studies of the company’s Decipher urologic cancer tests will be presented at the American Urological Association (AUA) Annual Meeting, taking place April 28-May 1, 2023, at McCormick Place in Chicago. The abstracts include findings from two separate, large-sc
Mar 15, 2023 04:15 pm ET
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics capabilities and offerings for biopharmaceutical partners will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Flo
Mar 11, 2023 12:11 pm ET
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
Veracyte, Inc. (Nasdaq: VCYT) outlined the company’s cash, cash equivalents and short-term investment status in light of the events surrounding Silicon Valley Bank (SVB).
Feb 27, 2023 05:00 pm ET
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences.
Feb 22, 2023 04:05 pm ET
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2022.
Feb 13, 2023 05:23 pm ET
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
Veracyte, Inc. (Nasdaq: VCYT) announced new data being presented this week at the 2023 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium which demonstrate that a gene expression signature derived from the company’s proprietary Decipher Genomics Resource for Intelligent Discovery (GRID) database may help physicians further persona
Feb 06, 2023 05:00 pm ET
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same da
Feb 01, 2023 04:05 pm ET
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.
Feb 01, 2023 08:32 am ET
Jan 23, 2023 09:00 am ET
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that Tina S. Nova, Ph.D. has been elected as Executive Chair of the Exagen Board of Directors, effective January 19, 2023. Dr. Nova succeeds Brian Birk,...
Dec 15, 2022 04:05 pm ET
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were
Nov 02, 2022 04:05 pm ET
Veracyte Announces Third Quarter 2022 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2022.
Nov 01, 2022 05:11 pm ET
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting the company’s unique, multi-omics immuno-oncology capabilities and offerings will be presented at the Society for Immunotherapy of Cancer’s 37th Annual Meeting & Pre-Conference Programs (SITC 2022), taking place November 8-12, 2022, in Boston.
Oct 27, 2022 05:00 pm ET
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Credit Suisse 31st Annual Healthcare Conference on Tuesday, November 8, at 1:25 p.m. Eastern Time.
Oct 25, 2022 08:30 am ET
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP) would benefit from dose-intensified salvage radiotherapy (SRT). The data, from a randomized, phase 3 trial
Oct 24, 2022 08:30 am ET
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced data that provide new insights into thyroid tumor behavior. The findings were derived from whole-transcriptome analyses of Veracyte’s extensive thyroid nodule database and were presented at the American Thyroid Association Annual Meeting, held October 19-23 in Montreal.
Oct 18, 2022 04:05 pm ET
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced that two abstracts highlighting the clinical value of the company’s Envisia Genomic Classifier and Percepta Nasal Swab tests in interstitial lung disease (ILD) and lung cancer, respectively, were presented as posters today at the American College of Chest Physicians (CHEST) Annual Meeting 2022, taking plac
Oct 13, 2022 05:00 pm ET
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the third quarter of 2022 after the close of market on Wednesday, November 2, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Sep 13, 2022 08:30 am ET
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
Veracyte, Inc. (Nasdaq: VCYT) announced today that John Leite, Ph.D., has joined the company as senior vice president and general manager of Pulmonology & Market Access. Dr. Leite’s responsibilities will include leading commercial activities for Veracyte’s lung portfolio, including market development for the noninvasive Percepta Nasal Swab test in lu
Sep 11, 2022 02:30 am ET
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company’s Decipher Prostate Genomic Classifier to identify men with advanced prostate cancer who are more likely to benefit from intensified treatment with abiraterone acetate
Sep 07, 2022 04:54 pm ET
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive therapy. These findings, shared at the
Sep 01, 2022 05:00 pm ET
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 2:55 p.m. Eastern Time.
Aug 31, 2022 07:00 am ET
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company’s genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris.
Aug 29, 2022 11:19 am ET
Aug 11, 2022 04:05 pm ET
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
Veracyte, Inc. (Nasdaq: VCYT) today announced the appointment of Eliav Barr, M.D., to its board of directors, effective immediately.
Aug 02, 2022 04:05 pm ET
Veracyte Announces Second Quarter 2022 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2022.
Jul 20, 2022 04:15 pm ET
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
Veracyte, Inc. (Nasdaq: VCYT) today announced that new clinical validation data published online in
Jul 14, 2022 04:30 pm ET
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2022 after the close of market on Tuesday, August 2, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Jun 27, 2022 08:15 am ET
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has been named a Bay Area Top Workplace for the ninth consecutive year.
Jun 20, 2022 08:15 am ET
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
Veracyte, Inc. (Nasdaq: VCYT) today announced that findings from a new meta-analysis provide real-world evidence that the Afirma Genomic Sequencing Classifier (GSC) can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules and that, when the test deems a nodule as suspicious, the patient’s risk of malignancy is consistent, a
Jun 03, 2022 08:30 am ET
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of data reinforcing the clinical utility of the Decipher Prostate genomic classifier for helping to guide the timing and intensity of therapy in men experiencing prostate cancer recurrence following radical prostatectomy (RP). The findings, from an ancillary study of the prospective open-l
May 26, 2022 05:10 pm ET
 New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from a large, population-based study reinforce the clinical utility of the Decipher Prostate genomic classifier. The findings, which will be shared for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, suggest that the Decipher Prostate tests
May 26, 2022 05:05 pm ET
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
Veracyte, Inc. (Nasdaq: VCYT) announced today new data from a clinical research study demonstrating the ability of its Immunoscore Immune Checkpoint (IC) assay to predict which patients with metastatic non-small cell lung cancer (NSCLC) may benefit from immune checkpoint inhibitors (ICIs). The findings will be shared in an oral presentation at the 20
May 26, 2022 08:15 am ET
Veracyte to Present at Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences. Veracyte will present at the William Blair 42nd Annual Growth Stock Conference on Wednesday, June 8, and will participate in a fireside chat at the G
May 16, 2022 04:17 pm ET
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening
May 12, 2022 04:36 pm ET
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated clinical guideline from the American Urological Association (AUA) and the American Society for Radiation Oncology (ASTRO) includes a new statement that is favorable for genomic testing, including the Decipher Prostate genomic classifier, to help guide care for men with localized prostate ca
May 12, 2022 08:30 am ET
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
Veracyte, Inc. (Nasdaq: VCYT) announced today that six abstracts demonstrating the ability of its genomic and immuno-oncology diagnostic tests and technology to improve outcomes for cancer patients will be shared at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in person and virtually from
May 04, 2022 08:30 am ET
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
Veracyte, Inc. (Nasdaq: VCYT) announced today that new consensus data from a survey of leading breast cancer oncologists in Europe suggest the importance of gene expression profile (GEP) testing in guiding treatment decisions for women with early-stage breast cancer. The findings, from the PROCURE study, were presented today at the European Society o
May 03, 2022 04:05 pm ET
Veracyte Announces First Quarter 2022 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2022.
May 02, 2022 04:01 pm ET
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of...
Apr 28, 2022 04:15 pm ET
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that three abstracts highlighting new data on the genomic underpinnings of prostate and bladder cancers will be presented at the American Urological Association Annual Meeting, taking place May 13-16, 2022, in New Orleans. The findings are derived from analyses of the Decipher GRID, a database that contai
Apr 26, 2022 04:05 pm ET
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that new, expanded data demonstrating the performance of the company’s non-invasive Percepta Nasal Swab test in the evaluation of potentially cancerous lung nodules will be presented at the American Thoracic Society (ATS) 2022 International Conference. The meeting will take place May 13-18, 2022
Apr 19, 2022 08:15 am ET
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2022 after the close of market on Tuesday, May 3, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Mar 01, 2022 04:05 pm ET
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a presentation at Cowen’s 42nd Annual Health Care Conference on March 8th at 12:50 p.m. Eastern Time.
Feb 28, 2022 04:05 pm ET
Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2021.
Feb 28, 2022 08:30 am ET
Veracyte Appoints Annie McGuire as General Counsel
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Annie McGuire as senior vice president and general counsel, effective immediately. Ms. McGuire will oversee all aspects of the company’s legal functions and will report to Marc Stapley, Veracyte’s chief executive officer.
Feb 22, 2022 08:30 am ET
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that it has appointed Jonathan Wygant as chief accounting officer, effective immediately. Mr. Wygant will oversee all aspects of the company’s global accounting operations, financial reporting and tax functions. He will report to Rebecca Chambers, Veracyte’s chief financial
Feb 15, 2022 08:30 am ET
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2021 after the close of market on Monday, February 28, 2022. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the s
Feb 14, 2022 07:30 pm ET
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced that new data validating the clinical utility of the company’s Decipher Prostate Genomic Classifier for guiding treatment selection in men with intermediate-risk prostate cancer will be presented Thursday, February 17, at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Symposium
Feb 08, 2022 04:05 pm ET
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, at 2:20 p.m. Eastern Time.
Jan 31, 2022 08:25 am ET
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data for the company’s Decipher urologic cancer tests will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif., and virtually, February 17-19, 2022.
Jan 24, 2022 08:30 am ET
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced the publication of new data that suggest the company’s Percepta Genomic Sequencing Classifier (GSC) can accelerate delivery of curative therapy for patients with high-risk lung nodules and inconclusive bronchoscopy results. The findings, from a prospective, randomized decision impact study
Jan 06, 2022 08:30 am ET
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
Veracyte, Inc. (Nasdaq: VCYT) today announced key leadership promotions that further position the company to achieve its strategic global vision. Effective immediately, Tina Nova, Ph.D., is president of Veracyte’s CLIA U.S. business, Stephane Debono is general manager of the company’s in vitro diagnostics (IVD) and EMEA organizations and Giulia
Dec 14, 2021 04:05 pm ET
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of clinical utility data confirming the ability of the Envisia Genomic Classifier to improve diagnostic and treatment decision-making for patients with idiopathic pulmonary fibrosis (IPF). The findings, which appear
Nov 24, 2021 04:32 am ET
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
Veracyte, Inc. (Nasdaq: VCYT) today announced that the Swedish Medical Technologies Product (MTP) Council has recommended the Prosigna Breast Cancer Assay for immediate reimbursement and clinical use in all Swedish healthcare regions without legal restrictions beginning November 22, 2021. The milestone follows recent G-BA reimbursement approval in Ge
Nov 13, 2021 07:00 am ET
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
Veracyte, Inc. (Nasdaq: VCYT) today announced that new data from three posters were presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, highlighting the company’s immuno-oncology offerings for biopharmaceutical and academic researchers.
Nov 09, 2021 04:05 pm ET
Veracyte Announces Third Quarter 2021 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2021.
Nov 05, 2021 08:15 am ET
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
Veracyte, Inc. (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO1 Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with localized colon cancer. The new guidelines appear online in
Nov 03, 2021 08:15 am ET
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate thyroid nodule cytology, as compared to the use of no molecular testing. The peer-reviewed paper appears online in
Nov 02, 2021 08:15 am ET
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
Veracyte, Inc. (Nasdaq: VCYT) today announced that three abstracts highlighting the company’s immuno-oncology offerings for biopharmaceutical researchers will be presented at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking place in Washington, DC and virtually, November 10-14, 2021.
Oct 26, 2021 09:25 am ET
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating the clinical utility of the company’s Decipher Prostate genomic classifier for guiding the timing and intensity of treatment in men experiencing prostate cancer progression following radical prostatectomy. The data, from a randomized, phase 3 trial conducted at 24 centers in Belgium, Germa
Oct 25, 2021 10:30 am ET
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced today that new data being presented at the American Society for Radiation Oncology (ASTRO) 2021 Annual Meeting suggest the company’s Decipher Prostate genomic classifier identifies patients with clinically high-risk prostate cancer who may require treatment intensification beyond standard-of-care therapy.
Oct 14, 2021 08:35 am ET
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
Veracyte, Inc. (Nasdaq: VCYT) announced that new data further validating the clinical utility of the company’s Decipher Prostate genomic test will be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2021 taking place October 24-27, 2021, in Chicago.
Oct 13, 2021 08:55 am ET
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
Veracyte, Inc., (Nasdaq: VCYT) announced today the publication of new data demonstrating that the company’s Decipher Bladder genomic classifier accurately identifies bladder tumors that are most likely to respond to chemotherapy prior to radical cystectomy. These findings could ultimately help physicians optimize treatment planning for their patients
Oct 12, 2021 04:58 pm ET
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2021 after the close of market on Tuesday, November 9. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Oct 12, 2021 04:05 pm ET
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Tuesday, November 9. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Oct 11, 2021 04:41 pm ET
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced new data demonstrating that the Envisia Genomic Classifier positively impacts clinical decision-making in idiopathic pulmonary fibrosis (IPF) by increasing diagnostic accuracy, physician confidence in diagnosis, and patient referral to appropriate therapy. The data, from a prospective, randomized decision-impact
Oct 11, 2021 08:15 am ET
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
Veracyte, Inc. (Nasdaq: VCYT) today announced that new expanded clinical validation data reinforce the ability of the company’s noninvasive Percepta Nasal Swab test to help physicians more accurately assess lung cancer risk in patients with lung nodules. The findings also show that the test delivers strong clinical performance across different nodule
Oct 06, 2021 08:30 am ET
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
Veracyte, Inc. (Nasdaq: VCYT) announced that four abstracts highlighting the clinical impact of the company’s genomic diagnostic tests for lung cancer and interstitial lung disease (ILD) will be presented at the American College of Chest Physicians (CHEST) Annual Meeting 2021, being held virtually October 17-20, 2021.
Sep 14, 2021 04:05 pm ET
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
Veracyte, Inc. (Nasdaq: VCYT) today announced that its Decipher® Prostate RP genomic classifier is uniquely recommended in the 2022 National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines for Oncology to guide treatment decisions for men with prostate cancer. The new guidelines specifically recommend Decipher P
Sep 01, 2021 08:35 am ET
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that it has appointed Joshua Klopper, M.D., as medical director of Endocrinology. Dr. Klopper is a nationally recognized endocrinologist who specializes in the evaluation and management of thyroid nodules and thyroid cancer. He joins Veracyte today, reporting to Rich
Aug 31, 2021 08:15 am ET
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley Virtual 19th Annual Global Healthcare Conference on Tuesday, September 14, at 3:30 p.m. Eastern Time.
Aug 23, 2021 10:33 am ET
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, announced today that it has been awarded a Top Workplaces honor by the Bay Area News Group for the eighth consecutive year.
Aug 03, 2021 08:00 am ET
Veracyte Completes Acquisition of HalioDx
Veracyte, Inc. (Nasdaq: VCYT) today announced the company has completed its acquisition of HalioDx to solidify its reach into global markets while expanding its scientific capabilities and diagnostics scope into 8 of the 10 top cancers as defined by U.S. incidence.
Jul 29, 2021 04:05 pm ET
Veracyte Announces Second Quarter 2021 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2021, and provided an update on recent business progress.
Jul 27, 2021 04:05 pm ET
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting the Decipher® Prostate Biopsy genomic classifier (GC) may help guide treatment decisions for prostate cancer patients who are candidates for active surveillance (AS). The findings, from a retrospective analysis of data from the MUSIC registry,
Jul 12, 2021 08:30 am ET
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Rebecca Chambers as executive vice president and chief financial officer. Ms. Chambers, a seasoned financial executive with a track record for scaling high-growth healthcare businesses, will join the company July 19, reporting to Marc Stapley, Vera
Jul 08, 2021 04:05 pm ET
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2021 after the close of market on Thursday, July 29. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Jul 08, 2021 08:30 am ET
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced key appointments that further strengthen its executive team and support the company’s global expansion. Rob Brainin will join the company as executive vice president and chief business officer and Bill Zondler has been appointed senior vice president and chief inform
Jul 06, 2021 02:00 am ET
Prosigna Breast Cancer Gene Signature Test Now Reimbursed in Germany
Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, today announced that the Prosigna® Breast Cancer Gene Signature Assay is now reimbursed by the statutory health insurances in Germany following a recent decision of the Federal Joint Committee (G-BA). The decision enables eligible patients in Germany with HR+/HER2- early-stage breast cancer to access the test and also underscores the growing importance of genomic testing for individualized treatment of patients.
Jul 01, 2021 08:45 am ET
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
“We couldn’t be more excited for Dr. Bulman and Dr. Marcom, two well-respected physicians with exceptional experience and credentials in their respective fields, to be part of the Veracyte team,” said Giulia C. Kennedy, Ph.D., Veracyte’s chief scientific officer and chief medical officer. “Their appointments demonstrate our sincere commitment to building a world-class medical team to support our growing menu of advanced genomic tests that address unmet needs throughout the patient journey. Their expertise will be especially critical as we prepare to launch new products and make these products
Jun 14, 2021 08:45 am ET
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
“These results suggest that the Decipher Prostate test may be a helpful tool to identify those patients who would benefit from early treatment intensification with androgen receptor inhibitors,” said Elai Davicioni, Ph.D., Veracyte’s senior vice president, Scientific and Clinical Operations, Urologic Cancers. “As the first clinical evaluation and demonstration of the Decipher test’s utility in the nmCRPC setting, this study adds meaningfully to prior evidence demonstrating the test’s ability to help inform treatment decisions and improve patient outcomes in multiple prostate cancer settings.”
Jun 04, 2021 09:24 am ET
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
Veracyte, Inc. (Nasdaq: VCYT) today announced that Medicare Administrative Contractors Palmetto GBA, WPS and CGS Administrators, LLC have finalized their coverage policies for Decipher Bladder, a genomic subtyping tool that helps physicians manage treatment decisions for patients with bladder cancer. These local coverage determinations (LCDs) make De
Jun 02, 2021 04:27 pm ET
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
Details of the Raymond James Human Health Innovation Conference have been corrected.
Jun 02, 2021 03:00 pm ET
Veracyte to Present at Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced that Marc Stapley, chief executive officer, and Bonnie Anderson, executive chairwoman, are scheduled to participate in two upcoming virtual investor conferences:
Jun 01, 2021 07:00 am ET
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
Veracyte, Inc. (Nasdaq: VCYT) today announced it has reached the terms of an agreement to acquire HalioDx in a transaction to further accelerate growth and strengthen Veracyte’s global leadership in cancer diagnostics.
May 26, 2021 03:00 pm ET
Veracyte to Present at Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc Stapley, incoming chief executive officer, are scheduled to participate in two upcoming virtual investor conferences:
May 26, 2021 09:05 am ET
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
Veracyte, Inc., (Nasdaq: VCYT) announced today new data that show the company’s Afirma Xpression Atlas (XA) can identify clinically relevant gene fusions in thyroid nodule samples collected via fine needle aspiration (FNA). The findings, which will be presented June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, support use
May 25, 2021 09:00 am ET
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
Veracyte, Inc. (Nasdaq: VCYT) today announced new data from two studies that further demonstrate the Decipher® Prostate Genomic Classifier (GC) provides prognostic information that can help physicians tailor treatment decisions for men with prostate cancer. The findings will be presented at the American Society of Clinical Oncology (ASCO) A
May 19, 2021 05:00 pm ET
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
Veracyte, Inc. (Nasdaq: VCYT) today announced pivotal clinical validation data showing that the company’s noninvasive nasal swab test can significantly improve the early assessment of lung cancer. The new findings show that the Percepta Nasal Swab, a first-of-its-kind genomic test, accurately classifies lung cancer risk in current or former smokers wi
May 18, 2021 05:15 pm ET
Veracyte to Present at Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman, chief executive officer and incoming executive chairman, and Marc Stapley, incoming chief executive officer, are scheduled to participate in two upcoming virtual investor conferences:
May 14, 2021 04:35 pm ET
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced that data reinforcing the diagnostic performance and utility of the Envisia® Genomic Classifier are being shared at the American Thoracic Society (ATS) 2021 International Conference, taking place today through May 18. The company is also presenting new data which demonstrate that the novel genomic tes
May 14, 2021 12:45 pm ET
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
Veracyte, Inc. (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta® Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis. Study findings presented today at the American Thoracic Society (ATS) 2021 International Co
May 10, 2021 04:10 pm ET
Veracyte, Inc. Announces CEO Succession Plan
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced its executive leadership succession plan, with industry veteran Marc Stapley to succeed Veracyte cofounder, Bonnie Anderson, as chief executive officer. Ms. Anderson will move into an active executive chairman role, serving as a trusted advisor to Mr. Stapley, for th
May 10, 2021 04:05 pm ET
Veracyte Announces First Quarter 2021 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2021, which were in line with its previously announced, preliminary first-quarter results. The company also provided an update on recent business progress.
May 04, 2021 04:45 pm ET
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress
Veracyte, Inc. (Nasdaq: VCYT) announced today that new data relating to the Prosigna® Breast Cancer Gene Signature Assay will be presented at the European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress 2021 taking place May 5-8.
Apr 29, 2021 08:30 am ET
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company with a presence in seven of the top ten cancers in the United States, announced today that six abstracts for its genomic tests in lung, prostate and thyroid cancers will be presented at the 2021 ASCO Annual Meeting, which will be held virtually June 4-8, 2021.
Apr 27, 2021 04:35 pm ET
Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of a new study that demonstrates the robust performance of the Percepta Genomic Sequencing Classifier (GSC), a novel genomic test, in helping to improve lung cancer diagnosis. The data, based on widely accepted community guidelines for establishing analytical validity, add to the growing bo
Apr 20, 2021 01:00 pm ET
Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the first quarter of 2021 after the close of market on Monday, May 10. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Apr 19, 2021 08:30 am ET
Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference
Veracyte, Inc. (Nasdaq: VCYT) announced today that new data demonstrating the clinical capability of the Percepta® Genomic Atlas for informing lung cancer treatment decisions, as well as the technical feasibility of enabling the company’s Envisia® Genomic Classifier on the nCounter Analysis System, will be presented at the Americ
Apr 15, 2021 04:05 pm ET
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) announced that Keith Kennedy, chief financial officer and chief operating officer, will retire from the company, effective May 15, 2021, following the company’s release of its full quarterly financial results and the filing of its Form 10-Q for the first quarter 2021. Jane Alley, vice president and corporate controller, w
Apr 14, 2021 08:30 am ET
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
Veracyte (Nasdaq: VCYT) today announced a key milestone in its companion diagnostics program with Acerta Pharma, the hematology research and development arm of AstraZeneca (LSE/STO/NYSE: AZN). The first patient has been enrolled and randomized in Acerta Pharma’s Phase 3 ESCALADE trial, which is using Veracyte’s LymphMark lymphoma subtyping test to identify p
Apr 02, 2021 08:15 am ET
Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 2:15 p.m. Eastern Time.
Mar 22, 2021 08:15 am ET
Veracyte Appoints Muna Bhanji to Its Board of Directors
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately.
Mar 15, 2021 08:30 am ET
Veracyte Completes Acquisition of Decipher Biosciences
Veracyte, Inc. (Nasdaq: VCYT) today announced it has completed its acquisition of Decipher Biosciences, Inc. to further solidify its global leadership in genomic diagnostics, with an expanded reach into 7 of the 10 most common cancers in the United States, while accelerating revenue growth.
Mar 10, 2021 05:15 pm ET
Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
Veracyte, Inc. (Nasdaq: VCYT) today commended the U.S. Preventive Services Task Force (USPSTF) for its new, revised recommendations that expand eligibility for lung cancer screening. The updated recommendations lower the age for current and former smokers to begin screening from 55 to 50 years and reduces smoking intensity – from a 30 “pack-year” hist
Feb 18, 2021 04:05 pm ET
Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021 at 3:40 p.m. Eastern Time.
Feb 17, 2021 04:05 pm ET
Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent business progress.
Feb 11, 2021 04:05 pm ET
Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Thursday, February 18, at 1:30 p.m. Eastern Time.
Feb 10, 2021 08:15 am ET
Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its full financial results for the fourth quarter and full-year 2020 after the close of market on Wednesday, February 17. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the s
Feb 09, 2021 04:15 pm ET
Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 8,547,297 shares of common stock, including 1,114,864 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $74.00 per share. The net proceeds to Veracyte from the offering were approximately $593.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Feb 04, 2021 10:45 pm ET
Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 7,432,433 shares of its common stock at a public offering price of $74.00 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be approximately $550 million. The public offering was upsized from the previously announced size of $400 million in shares of common stock. All of the shares are being offered by the Company. The offering is expected to close on or a
Feb 03, 2021 04:32 pm ET
Veracyte Announces Proposed Public Offering of Common Stock
Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of $400.0 million in shares of its common stock. All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $60.0 million in shares of its common stock at the public offering price, less underwriting discounts and commissions.
Feb 03, 2021 07:05 am ET
Veracyte to Acquire Decipher Biosciences
Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while acceleratin
Feb 03, 2021 07:00 am ET
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced preliminary results for the fourth quarter and full year ended December 31, 2020.
Jan 06, 2021 02:00 pm ET
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021, at 4:15 p.m. Eastern Time.
Dec 22, 2020 08:15 am ET
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program will
Dec 22, 2020 08:15 am ET
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
Bayer and Veracyte (Nasdaq: VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte’s Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients’ tumors. The program wil
Dec 21, 2020 08:15 am ET
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
Veracyte, Inc. (Nasdaq: VCYT) today announced that the company has received ISO 13485:2016 certification for its Quality Management System (QMS) for the design, development and manufacture of genomic in vitro diagnostic (IVD) tests that aid in the diagnosis and prognosis of cancer and other diseases. The achievement is a key milestone in the company’s
Dec 16, 2020 12:00 pm ET
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
“We are excited to bring forward novel tests that we believe will address significant unmet needs throughout the patient journey in lung cancer,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “The preliminary data we presented today give us further confidence that our expanding portfolio of tests will improve the lives of patients through earlier diagnosis and comprehensive genomic profiling. This progress, on the heels of our expanded collaboration with the Lung Cancer Initiative at Johnson & Johnson, underscores our deep commitment to fighting this devastating diseas
Dec 15, 2020 08:15 am ET
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
Veracyte, Inc. (Nasdaq: VCYT) today announced it has expanded its
Dec 03, 2020 02:30 pm ET
Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, will host a Virtual Lung Cancer R&D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST.
Nov 23, 2020 04:05 pm ET
Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie Anderson, chairman and chief executive officer, will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held December 1-3, 2020.
Nov 17, 2020 09:45 am ET
Veracyte Announces New General Manager Structure to Advance Global Expansion
Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company also announced that Morten Frost will join the company as GM, pulmonology. Both
Nov 17, 2020 08:30 am ET
Veracyte Announces New General Manager Structure to Advance Global Expansion
Veracyte (Nasdaq: VCYT) today announced a new general manager-based structure to advance the company’s growing roster of genomic tests and its global expansion. John Hanna, currently chief commercial officer, will become GM, endocrinology, breast cancer and lymphoma. The company also announced that Morten Frost will join the company as GM, pulmonology. Both
Nov 02, 2020 04:05 pm ET
Veracyte Announces Third Quarter 2020 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the third quarter ended September 30, 2020 and provided an update on recent business progress. For the third quarter of 2020, revenue was $31.1 million, compared to $20.7 million in the second quarter of 2020 and $31.0 million in the third quarter of 2019. Product and testing revenue
Oct 30, 2020 08:15 am ET
Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
Veracyte, Inc., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the
Oct 22, 2020 04:05 pm ET
Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of a manuscript detailing the development of the company’s next-generation Percepta® Genomic Sequencing Classifier (GSC), which is used to improve lung cancer diagnosis among patients with suspicious lung nodules and inconclusive bronchoscopy results. The paper, published online
Oct 19, 2020 08:15 am ET
Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020
Veracyte, Inc., (Nasdaq: VCYT) today announced that new data presented at the CHEST Annual Meeting 2020 show that a genomic smoking index developed for use on samples obtained from the main lung airway can also be detected in nasal samples. The findings, shared in an oral presentation at the virtual meeting, reinforce the foundational “field of injury
Oct 14, 2020 04:05 pm ET
Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020
Veracyte, Inc. (Nasdaq: VCYT) announced today that an oral presentation will be given at the CHEST Annual Meeting 2020 reinforcing the foundational technology behind its noninvasive nasal swab test to identify lung cancer risk in patients with lung nodules. The meeting, hosted by the American College of Chest Physicians, is being held virtually Octob
Oct 07, 2020 08:15 am ET
Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the third quarter of 2020 after the close of market on Monday, November 2, 2020. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern time on the same day.
Sep 24, 2020 08:15 am ET
Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
Veracyte, Inc. (Nasdaq: VCYT) announced today that the Centers for Medicare and Medicaid Services (CMS) has approved new Advanced Diagnostic Laboratory Test (ADLT) status for the Envisia® Genomic Classifier. The determination confirms that the Envisia classifier meets the criteria for ADLT status under the Protecting Access to Medicare Act
Sep 15, 2020 04:30 pm ET
Veracyte to Present at Two Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to participate in two virtual investor conferences this week:
Sep 14, 2020 01:45 pm ET
Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director
Veracyte, Inc. (Nasdaq: VCYT) announced today that it has promoted Richard T. Kloos, M.D., to executive medical director, overseeing Veracyte’s global medical affairs in all clinical areas addressed by the company’s expanding menu of advanced genomic tests. Dr. Kloos, who previously served as senior medical director, endocrinology, will continue repor
Sep 11, 2020 08:15 am ET
Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
Veracyte, Inc. (Nasdaq: VCYT) announced today the initiation of a European study that will utilize the Delphi methodology to generate consensus regarding the clinical utility of genomic tests in breast cancer treatment. Led by an independent scientific committee of breast cancer experts with input from 180 breast cancer clinicians practicing in 12 Eur
Sep 04, 2020 08:15 am ET
Veracyte to Present at Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to participate in two upcoming virtual investor conferences:
Aug 24, 2020 08:15 am ET
Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year
Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year. The annual award is based solely on employee feedback gathered through an anonymous, third-party survey.
Aug 07, 2020 04:15 pm ET
Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $30.00 per share. The net proceeds to Veracyte from the offering were approximately $194 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Aug 05, 2020 04:15 pm ET
Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
Lung cancer is the leading cause of cancer deaths, and will kill approximately 136,000 Americans this year – more than the next three leading cancers combined. Lung nodules are typically the first sign of lung cancer, however, determining which lung nodules are cancerous and which are benign is often challenging, leading to unnecessary invasive procedures or delayed treatment.
Aug 05, 2020 08:15 am ET
Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
Veracyte, Inc. (Nasdaq: VCYT) today announced the publication of new data demonstrating that the Percepta® classifier significantly reduces invasive procedures in lung cancer diagnosis by classifying nearly 40 percent of patients as “low risk” when bronchoscopy is inconclusive. The findings, from a large, prospective clinical study involvin
Aug 04, 2020 07:27 pm ET
Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share. The gross proceeds to the Company from this offering, before deducting underwriting discounts and commissions and offering expenses payable by Veracyte, are expected to be $180.0 million. All of the shares are being offered by the Company. The offering is expected to close on or about August 7, 2020, subject to customary closing conditions. In addition, the Company granted to the underwriters partici
Aug 03, 2020 04:10 pm ET
Veracyte Announces Proposed Public Offering of Common Stock
Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Veracyte. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to 900,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
Jul 30, 2020 04:05 pm ET
Veracyte Announces Second Quarter 2020 Financial Results
Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress.
Jul 30, 2020 08:15 am ET
Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery
Veracyte, Inc. (Nasdaq: VCYT) today announced new study results showing that use of the Envisia® Genomic Classifier improves physicians’ ability to diagnose idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) without the need for surgery. The findings are published online in the
Jul 29, 2020 08:15 am ET
Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System
Veracyte, Inc. (Nasdaq: VCYT) and MAVIDx today announced an agreement for MAVIDx to develop ultra-high throughput gen
Jul 27, 2020 08:15 am ET
Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary
Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, today announced the addition of Jens Holstein to the company’s board of directors and the appointment of Jim Erlinger as executive vice president, general counsel and secretary.
Jul 16, 2020 08:15 am ET
Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release its financial results for the second quarter of 2020 after the close of market on Thursday, July 30, 2020. Company management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern time on the same day.
Jun 11, 2020 07:30 am ET
Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis
Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of an independent study showing that the Envisia Genomic Classifier enables physicians to more confidently diagnose idiopathic pulmonary fibrosis (IPF), a progressive lung disease, when results from high-resolution CT (HRCT) imaging are not definitive. The real-world clinical findings appea

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.